Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06099782
Title	A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	NCT06099782
Indications	skin melanoma lung non-small cell carcinoma renal cell carcinoma
Therapies	MK-3475A Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| POL \| NZL \| FRA \| AUS \| ARG